MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526008 | Name: Piromidic acid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piromidic acid is antibacterial against mainly gram negative organisms. It is used for urinary tract and intestinal infections.

Chemical Structure

Piromidic acid
Piromidic acid
CAS#19562-30-2

Theoretical Analysis

MedKoo Cat#: 526008

Name: Piromidic acid

CAS#: 19562-30-2

Chemical Formula: C14H16N4O3

Exact Mass: 288.1222

Molecular Weight: 288.31

Elemental Analysis: C, 58.32; H, 5.59; N, 19.43; O, 16.65

Price and Availability

Size Price Availability Quantity
100mg USD 215.00
500mg USD 445.00
1g USD 725.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Piromidic acid; Acidum piromidicum [INN-Latin]; Actrun C; Bactramyl; BRN 0625004; EINECS 243-161-4; Enterol; Gastrurol; Panacid; PD 93; PD-93; Pirodal; Piromidic acid.
IUPAC/Chemical Name
8-Ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acid
InChi Key
RCIMBBZXSXFZBV-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H16N4O3/c1-2-17-8-10(13(20)21)11(19)9-7-15-14(16-12(9)17)18-5-3-4-6-18/h7-8H,2-6H2,1H3,(H,20,21)
SMILES Code
O=C(C1=CN(CC)C2=NC(N3CCCC3)=NC=C2C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Piromidic acid is an antibacterial agent.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
Chloroform 1.0 3.47
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 288.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Guiberteau Cabanillas A, Ortiz Burguillos JM, Martínez Cañas MA, Rodríguez Cáceres MI, Salinas López F. Square wave adsorptive stripping voltammetric determination of piromidic acid. Application in urine. J Pharm Biomed Anal. 2003 Nov 24;33(4):553-62. PubMed PMID: 14623580. 2: Durán Merás I, Galeano Díaz T, Salinas López F, Rodríguez Cacéres MI. Determination of piromidic acid residues in trout muscle tissue and in urine by liquid chromatography with post-column modification of pH and fluorimetric detection. J Chromatogr B Biomed Sci Appl. 1998 Oct 23;718(1):135-41. PubMed PMID: 9832370. 3: Munns RK, Turnipseed SB, Pfenning AP, Roybal JE, Holland DC, Long AR, Plakas SM. Liquid chromatographic determination of flumequine, nalidixic acid, oxolinic acid, and piromidic acid residues in catfish (Ictalurus punctatus). J AOAC Int. 1998 Jul-Aug;81(4):825-38. PubMed PMID: 9680708. 4: Rostin M, Paux G, Sorbette F, Noblet C, Moore N, Boismare F, Montastruc P. [2 epidemics of acute kidney failure caused by piromidic acid]. Therapie. 1988 Aug-Sep;43(5):426-7. French. PubMed PMID: 3227506. 5: Horie M, Saito K, Hoshino Y, Nose N, Mochizuki E, Nakazawa H. Simultaneous determination of nalidixic acid, oxolinic acid and piromidic acid in fish by high-performance liquid chromatography with fluorescence and UV detection. J Chromatogr. 1987 Jul 31;402:301-8. PubMed PMID: 3654871. 6: Corelli F, Massa S, Stefancich G, Artico M, Panico S, Simonetti N. Researches on antibacterial and antifungal agents. II - Synthesis of 1-ethyl-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)quinoline-3-carboxylic acid, a novel highly active, broad-spectrum antibacterial agent related to piromidic acid. Farmaco Sci. 1984 Feb;39(2):95-109. PubMed PMID: 6425079. 7: Godin M, Ducastelle T, Bercoff E, Dubois D, Fillastre JP, Bourreille J. [Acute renal failure after treatment with piromidic acid]. Presse Med. 1983 May 14;12(21):1363-4. French. PubMed PMID: 6222321. 8: García-Rodriguez JA, Gómez-García AC, Rodrigo N, Sáenz MC. Activity of beta-hydroxy-piromidic acid against Staphylococcus aureus and enterobacteriaceae. J Antimicrob Chemother. 1982 Jun;9(6):493-5. PubMed PMID: 7107550. 9: Rossi E, Silvestri MG, Manari A, Savazzi G, Migone L. Acute renal failure and piromidic acid. Nephron. 1982;32(1):80-2. PubMed PMID: 7177284. 10: Takeda Y, Kanaya H. Formation of nitroso compounds and mutagens from cinnarizine, ethambutol, piromidic acid, pyridinol carbamate and tiaramide by drug/nitrite interaction. Cancer Lett. 1982 Jan;15(1):53-9. PubMed PMID: 7037170. 11: Johansen KS, Grosen G, Holm-Nielsen E, Jacobsen J, Jensen SH, Juel-Jacobsen T, Skinhøj A, Laursen H. [Patients with symptoms of acute urinary infections treated with piromidic acid or sulfamethizole in general practice. A double-blind clinical controlled multicentre study]. Ugeskr Laeger. 1981 Sep 21;143(39):2491-4. Danish. PubMed PMID: 7029845. 12: Preusler A, Graben N, Bock KD. [Acute kidney failure caused by piromidic acid]. Dtsch Med Wochenschr. 1981 Apr 17;106(16):515-6. German. PubMed PMID: 7215176. 13: Matsumoto J, Minamida A, Kimura Y, Minami S. Pyrido[2,3-d]pyrimidine antibacterial agents. IV. Synthesis of metabolites of piromidic acid. Chem Pharm Bull (Tokyo). 1980 Aug;28(8):2531-6. PubMed PMID: 7428132. 14: Grossi F, Goisis F, Goisis C. [Clinical study of the use of piromidic acid in urinary tract infections in pregnant and puerperal hospitalized patients]. Clin Ter. 1979 Sep 30;90(6):579-90. Italian. PubMed PMID: 535334. 15: Grima P. [In vitro activity of 2 quinoline derivatives, oxolinic and piromidic acid]. Boll Chim Farm. 1979 Jul;118(7):363-7. Italian. PubMed PMID: 526354. 16: Garcia Rodgriguez JA, Gomez Garcia AC, Saenz Gonzalez MC. In vitro susceptibility studies with piromidic acid. J Antimicrob Chemother. 1978 May;4(3):289-91. PubMed PMID: 670126. 17: Greenwood D. The activity of pipemidic acid and piromidic acid against Escherichia coli in static culture and in conditions stimulating the treatment of bacterial cystitis. J Appl Bacteriol. 1978 Apr;44(2):191-7. PubMed PMID: 346547. 18: Sekine Y, Miyamoto M, Hashimoto M, Nakamura K. Metabolism of piromidic acid, a new antibacterial agent. V. Pharmacokinetics of priomidic acid in humans. Chem Pharm Bull (Tokyo). 1977 Sep;25(9):2203-10. PubMed PMID: 589722. 19: Yamabe S, Shimizu M. Combination effects of chemotherapeutic agents. I. Antagonistic effects of 1,10-phenantbroline with nalidixic acid and piromidic acid on the growth of Escherichia coli. J Antimicrob Chemother. 1977 Jan;3(1):101-4. PubMed PMID: 321411. 20: Sekine Y, Miyamoto M, Hashimoto M, Nakamura K. Metabolism of piromidic acid, a new antibacterial agent. IV. Pharmacokinetics of piromidic acid in rats. Chem Pharm Bull (Tokyo). 1976 Jul;24(7):1462-70. PubMed PMID: 975418.